1. Home
  2. KEN vs EVO Comparison

KEN vs EVO Comparison

Compare KEN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KEN
  • EVO
  • Stock Information
  • Founded
  • KEN 2014
  • EVO 1993
  • Country
  • KEN Singapore
  • EVO Germany
  • Employees
  • KEN N/A
  • EVO N/A
  • Industry
  • KEN Electric Utilities: Central
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • KEN Utilities
  • EVO Health Care
  • Exchange
  • KEN Nasdaq
  • EVO Nasdaq
  • Market Cap
  • KEN 1.5B
  • EVO 1.6B
  • IPO Year
  • KEN N/A
  • EVO 2021
  • Fundamental
  • Price
  • KEN $29.43
  • EVO $4.44
  • Analyst Decision
  • KEN
  • EVO Buy
  • Analyst Count
  • KEN 0
  • EVO 2
  • Target Price
  • KEN N/A
  • EVO $5.90
  • AVG Volume (30 Days)
  • KEN 10.3K
  • EVO 238.2K
  • Earning Date
  • KEN 12-27-2024
  • EVO 11-06-2024
  • Dividend Yield
  • KEN 12.81%
  • EVO N/A
  • EPS Growth
  • KEN N/A
  • EVO N/A
  • EPS
  • KEN 3.23
  • EVO N/A
  • Revenue
  • KEN $742,796,000.00
  • EVO $866,665,179.00
  • Revenue This Year
  • KEN N/A
  • EVO $4.56
  • Revenue Next Year
  • KEN N/A
  • EVO $13.44
  • P/E Ratio
  • KEN $9.00
  • EVO N/A
  • Revenue Growth
  • KEN 8.29
  • EVO N/A
  • 52 Week Low
  • KEN $19.63
  • EVO $2.85
  • 52 Week High
  • KEN $31.26
  • EVO $12.00
  • Technical
  • Relative Strength Index (RSI)
  • KEN 48.30
  • EVO 45.00
  • Support Level
  • KEN $29.35
  • EVO $4.39
  • Resistance Level
  • KEN $30.12
  • EVO $4.81
  • Average True Range (ATR)
  • KEN 0.65
  • EVO 0.14
  • MACD
  • KEN -0.23
  • EVO -0.07
  • Stochastic Oscillator
  • KEN 29.76
  • EVO 0.00

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: